📊 BPTH Key Takeaways
Is Bio-Path Holdings, Inc.. (BPTH) a Good Investment?
Bio-Path Holdings is in critical financial distress with zero revenue, negative stockholders' equity of -$8.0M, and severe liquidity constraints (0.08x current ratio). The company is burning cash at -$1.6M annually with no operating income while carrying $8.7M in liabilities against only $690K in assets, indicating imminent solvency risk.
BIO-PATH HOLDINGS shows extremely weak fundamentals: it has no revenue, continues to post sizable operating and net losses, and is consuming cash without an operating base to support the business. The balance sheet is severely distressed, with zero cash, negative equity, and very poor liquidity, which raises major doubt about financial sustainability unless external funding materially improves its position.
Why Buy Bio-Path Holdings, Inc.. Stock? BPTH Key Strengths
- No long-term debt obligations reducing refinancing risk
- Minimal capital expenditure requirements suggesting asset-light operations
- EPS improvement of 87.7% YoY indicates reduced dilution rate
- No long-term debt reduces traditional balance-sheet leverage risk
- Capital expenditure requirements are minimal, limiting cash drain from fixed-asset investment
- EPS improved year over year, indicating some reduction in per-share loss even though absolute profitability remains very weak
BPTH Stock Risks: Bio-Path Holdings, Inc.. Investment Risks
- Negative stockholders' equity of -$8.0M indicates balance sheet insolvency
- Zero revenue generation with -$8.3M operating loss signals complete operational failure
- Critical liquidity crisis with $0 cash and 0.08x current ratio threatening going concern status
- Negative free cash flow of -$1.6M draining remaining capital resources
- Total liabilities ($8.7M) exceed total assets ($690K) by 12.6x indicating balance sheet collapse
- No revenue generation means losses are not being offset by any commercial operations
- Negative stockholders' equity and a current ratio of 0.08x indicate severe financial stress
- Negative operating and free cash flow with zero cash creates high near-term funding risk
Key Metrics to Watch
- Cash runway and path to positive cash flow
- Revenue re-initiation and clinical trial progress
- Debt restructuring or capital raise announcements
- Stockholders' equity trajectory back to positive
- Monthly cash burn rate and operating expense reduction
- Cash runway and new financing activity
- Revenue emergence and operating cash burn trend
Bio-Path Holdings, Inc.. (BPTH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BPTH Profit Margin, ROE & Profitability Analysis
BPTH vs Healthcare Sector: How Bio-Path Holdings, Inc.. Compares
How Bio-Path Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Bio-Path Holdings, Inc.. Stock Overvalued? BPTH Valuation Analysis 2026
Based on fundamental analysis, Bio-Path Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Bio-Path Holdings, Inc.. Balance Sheet: BPTH Debt, Cash & Liquidity
BPTH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Bio-Path Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-33.63 indicates the company is currently unprofitable.
BPTH Revenue Growth, EPS Growth & YoY Performance
BPTH Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2017 | N/A | -$1.6M | N/A |
| Q2 2017 | N/A | -$1.9M | N/A |
| Q1 2017 | N/A | -$397.0K | N/A |
| Q3 2016 | N/A | -$1.5M | N/A |
| Q2 2016 | N/A | -$1.1M | N/A |
| Q1 2016 | N/A | -$1.4M | N/A |
| Q3 2015 | N/A | -$1.1M | N/A |
| Q2 2015 | N/A | -$1.1M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Bio-Path Holdings, Inc.. Dividends, Buybacks & Capital Allocation
BPTH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Bio-Path Holdings, Inc.. (CIK: 0001133818)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BPTH
What is the AI rating for BPTH?
Bio-Path Holdings, Inc.. (BPTH) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 96% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BPTH's key strengths?
Claude: No long-term debt obligations reducing refinancing risk. Minimal capital expenditure requirements suggesting asset-light operations. ChatGPT: No long-term debt reduces traditional balance-sheet leverage risk. Capital expenditure requirements are minimal, limiting cash drain from fixed-asset investment.
What are the risks of investing in BPTH?
Claude: Negative stockholders' equity of -$8.0M indicates balance sheet insolvency. Zero revenue generation with -$8.3M operating loss signals complete operational failure. ChatGPT: No revenue generation means losses are not being offset by any commercial operations. Negative stockholders' equity and a current ratio of 0.08x indicate severe financial stress.
What is BPTH's revenue and growth?
Bio-Path Holdings, Inc.. reported revenue of $0.0.
Does BPTH pay dividends?
Bio-Path Holdings, Inc.. does not currently pay dividends.
Where can I find BPTH SEC filings?
Official SEC filings for Bio-Path Holdings, Inc.. (CIK: 0001133818) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BPTH's EPS?
Bio-Path Holdings, Inc.. has a diluted EPS of $-1.07.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BPTH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Bio-Path Holdings, Inc.. has a STRONG SELL rating with 96% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BPTH stock overvalued or undervalued?
Valuation metrics for BPTH: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BPTH stock in 2026?
Our dual AI analysis gives Bio-Path Holdings, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BPTH's free cash flow?
Bio-Path Holdings, Inc..'s operating cash flow is $-1.6M, with capital expenditures of $21.0K.
How does BPTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.08 (avg: 2).